A Randomized, Open label, Multicentric, Comparative, Efficacy and Safety study of Early initiation Triple Oral Therapy of Fixed dose combination [FDC] of Glimepiride + Metformin SR + Pioglitazone Vs Fixed dose combination [FDC] of Dual oral therapy of Glimepiride + Metformin SR in patients with type 2 diabetes inadequately controlled with monotherapy of either Glimepiride or Metformin Plain/SR formulation.

Trial Profile

A Randomized, Open label, Multicentric, Comparative, Efficacy and Safety study of Early initiation Triple Oral Therapy of Fixed dose combination [FDC] of Glimepiride + Metformin SR + Pioglitazone Vs Fixed dose combination [FDC] of Dual oral therapy of Glimepiride + Metformin SR in patients with type 2 diabetes inadequately controlled with monotherapy of either Glimepiride or Metformin Plain/SR formulation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Pioglitazone (Primary) ; Glimepiride; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 23 Nov 2011 Status changed from recruiting to completed as reported by Clinical Trials Registry - India record.
    • 10 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top